Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL
Status:
Terminated
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized double blind placebo controlled study of azacitidine with or without
birinapant in subjects with higher risk Myelodysplastic syndrome, secondary MDS or
myelomonocytic leukemia (CMMoL) who are naïve, to azacitidine therapy. Pre-clinical and
mechanistic studies support that azacitidine may modulate pathways that enable
birinapant-mediated anti-tumor activity.